Literature DB >> 21473912

Cannabinoid CB1 receptors regulate neuronal TNF-α effects in experimental autoimmune encephalomyelitis.

Silvia Rossi1, Roberto Furlan, Valentina De Chiara, Luca Muzio, Alessandra Musella, Caterina Motta, Valeria Studer, Francesca Cavasinni, Giorgio Bernardi, Gianvito Martino, Benjamin F Cravatt, Beat Lutz, Mauro Maccarrone, Diego Centonze.   

Abstract

Cannabinoid CB1 receptors (CB1Rs) regulate the neurodegenerative damage of experimental autoimmune encephalomyelitis (EAE) and of multiple sclerosis (MS). The mechanism by which CB1R stimulation exerts protective effects is still unclear. Here we show that pharmacological activation of CB1Rs dampens the tumor necrosis factor α (TNFα)-mediated potentiation of striatal spontaneous glutamate-mediated excitatory postsynaptic currents (EPSCs), which is believed to cogently contribute to the inflammation-induced neurodegenerative damage observed in EAE mice. Furthermore, mice lacking CB1Rs showed a more severe clinical course and, in parallel, exacerbated alterations of sEPSC duration after induction of EAE, indicating that endogenous cannabinoids activate CB1Rs and mitigate the synaptotoxic action of TNFα in EAE. Consistently, we found that mice lacking the fatty acid amide hydrolase (FAAH), and thus expressing abnormally high brain levels of the endocannabinoid anandamide, developed a less severe EAE associated with preserved TNFα-induced sEPSC alterations. CB1Rs are important modulators of EAE pathophysiology, and might play a mechanistic role in the neurodegenerative damage of MS patients.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21473912     DOI: 10.1016/j.bbi.2011.03.017

Source DB:  PubMed          Journal:  Brain Behav Immun        ISSN: 0889-1591            Impact factor:   7.217


  36 in total

1.  Sativex(®) and clinical-neurophysiological measures of spasticity in progressive multiple sclerosis.

Authors:  Letizia Leocani; Arturo Nuara; Elise Houdayer; Irene Schiavetti; Ubaldo Del Carro; Stefano Amadio; Laura Straffi; Paolo Rossi; Vittorio Martinelli; Carlos Vila; Maria Pia Sormani; Giancarlo Comi
Journal:  J Neurol       Date:  2015-08-20       Impact factor: 4.849

2.  Endocannabinoids exert CB1 receptor-mediated neuroprotective effects in models of neuronal damage induced by HIV-1 Tat protein.

Authors:  Changqing Xu; Douglas J Hermes; Blessing Nwanguma; Ian R Jacobs; Kenneth Mackie; Somnath Mukhopadhyay; Aron H Lichtman; Bogna Ignatowska-Jankowska; Sylvia Fitting
Journal:  Mol Cell Neurosci       Date:  2017-07-19       Impact factor: 4.314

Review 3.  Neuroprotection in Oxidative Stress-Related Neurodegenerative Diseases: Role of Endocannabinoid System Modulation.

Authors:  Janos Paloczi; Zoltan V Varga; George Hasko; Pal Pacher
Journal:  Antioxid Redox Signal       Date:  2017-07-18       Impact factor: 8.401

4.  Neuroprotective effects of fatty acid amide hydrolase catabolic enzyme inhibition in a HIV-1 Tat model of neuroAIDS.

Authors:  Douglas J Hermes; Changqing Xu; Justin L Poklis; Micah J Niphakis; Benjamin F Cravatt; Ken Mackie; Aron H Lichtman; Bogna M Ignatowska-Jankowska; Sylvia Fitting
Journal:  Neuropharmacology       Date:  2018-08-13       Impact factor: 5.250

5.  Systems biology analysis of the endocannabinoid system reveals a scale-free network with distinct roles for anandamide and 2-arachidonoylglycerol.

Authors:  Nicola Bernabò; Barbara Barboni; Mauro Maccarrone
Journal:  OMICS       Date:  2013-10-11

Review 6.  Endocannabinoid signalling and the deteriorating brain.

Authors:  Vincenzo Di Marzo; Nephi Stella; Andreas Zimmer
Journal:  Nat Rev Neurosci       Date:  2015-01       Impact factor: 34.870

Review 7.  Neuroprotection in Experimental Autoimmune Encephalomyelitis and Progressive Multiple Sclerosis by Cannabis-Based Cannabinoids.

Authors:  Gareth Pryce; Dieter R Riddall; David L Selwood; Gavin Giovannoni; David Baker
Journal:  J Neuroimmune Pharmacol       Date:  2014-12-24       Impact factor: 4.147

8.  Glatiramer acetate protects against inflammatory synaptopathy in experimental autoimmune encephalomyelitis.

Authors:  Antonietta Gentile; Silvia Rossi; Valeria Studer; Caterina Motta; Valentina De Chiara; Alessandra Musella; Helena Sepman; Diego Fresegna; Gabriele Musumeci; Giorgio Grasselli; Nabila Haji; Sagit Weiss; Liat Hayardeny; Georgia Mandolesi; Diego Centonze
Journal:  J Neuroimmune Pharmacol       Date:  2013-01-31       Impact factor: 4.147

9.  Neuroprotective Effect Is Driven Through the Upregulation of CB1 Receptor in Experimental Autoimmune Encephalomyelitis.

Authors:  Zhi-Yin Lou; Wen-Bo Yu; Jie Chen; Lin Li; Li-Sheng Jiang; Bao-Guo Xiao; Zhen-Guo Liu
Journal:  J Mol Neurosci       Date:  2015-09-28       Impact factor: 3.444

10.  Selective CB2 receptor activation ameliorates EAE by reducing Th17 differentiation and immune cell accumulation in the CNS.

Authors:  Weimin Kong; Hongbo Li; Ronald F Tuma; Doina Ganea
Journal:  Cell Immunol       Date:  2013-11-14       Impact factor: 4.868

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.